Perspective Therapeutics: Definitely Not Looking Overvalued Now

When I first covered Perspective Therapeutics (NYSE: CATX ) earlier this year , I expressed interest and optimism for their approach of a novel peptide receptor radionuclide therapy (PRRT), which could be of use inI have my PhD in biochemistry and have worked for years analyzing clinical trials and biotech companies. It is my passion to educate everyone possible on the science behind the businesses that we invest in, and it's my mission to help you do your due diligence and not get burned by the pitfalls of ...